UBS Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

UBS Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-50	Closed	-$1K	–	8832
2015 Q4	$1K	Hold	50	–	–	﹤0.01%	8265
2015 Q3	$1K	Hold	50	–	–	﹤0.01%	8331
2015 Q2	$1K	Buy	+50	New	+$965	﹤0.01%	8406

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

UBS Group's CTIC Position: Q2 2023 in Review

UBS Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 402,893 shares — an estimated $1.69M sold.

UBS Group first reported a position in CTIC in Q4 2014 and held it in 34 quarters. The position peaked at $5.57M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

UBS Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 402,893 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $1.69M.
UBS Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 34 quarters.
UBS Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.57M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.